Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison

Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis

(2016) Robert J. Fox et al.   CURRENT MEDICAL RESEARCH AND OPINION

The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis

(2016) Benedikt Kretzschmar et al.   Current Neurology and Neuroscience Reports

The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada

(2016) Wenqing Su et al.   JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States

(2016) Josephine Mauskopf et al.   JOURNAL OF MEDICAL ECONOMICS

Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective

(2016) Julie Chevalier et al.   PLoS One

Dimethyl Fumarate: A Review in Relapsing-Remitting MS

(2015) Emma D. Deeks   DRUGS

Adjusted Indirect Comparison of Oral Multiple Sclerosis Agents

(2015) H Metin et al.   VALUE IN HEALTH

The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada

(2015) Emily Dorman et al.   JOURNAL OF MEDICAL ECONOMICS

Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis

(2014) Francisco J. Zagmutt et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Cost-Effectiveness Of Delayed-Release Dimethyl Fumarate Compared To Glatiramer Acetate And Fingolimod For The Treatment Of Relapsing-Remitting Multiple Sclerosis

(2014) J.A. Mauskopf et al.   VALUE IN HEALTH

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials

(2014) Vissia Viglietta et al.   Annals of Clinical and Translational Neurology

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

(2013) Fred D. Lublin et al.   ANNALS OF NEUROLOGY

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison

(2013) Michael Hutchinson et al.   CURRENT MEDICAL RESEARCH AND OPINION

BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety

(2013) Robert J. Fox et al.   CURRENT MEDICAL RESEARCH AND OPINION

Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod

(2012) N.S. Roskell et al.   CURRENT MEDICAL RESEARCH AND OPINION

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorde

(2012) James Signorovitch et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research

(2012) James E. Signorovitch et al.   VALUE IN HEALTH

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Comparative Efficacy of Vildagliptin and Sitagliptin in Japanese Patients with Type 2 Diabetes Mellitus

(2011) James E. Signorovitch et al.   CLINICAL DRUG INVESTIGATION

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

(2011) James E. Signorovitch et al.   CURRENT MEDICAL RESEARCH AND OPINION

Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1

(2011) Jeroen P. Jansen et al.   VALUE IN HEALTH

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

(2010) V. Devonshire et al.   EUROPEAN JOURNAL OF NEUROLOGY

Comparative Effectiveness Without Head-to-Head Trials

(2010) James E. Signorovitch et al.   PHARMACOECONOMICS

Study Design, Precision, and Validity in Observational Studies

(2009) Melissa D.A. Carlson et al.   JOURNAL OF PALLIATIVE MEDICINE

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

(2009) D. Cadavid et al.   NEUROLOGY

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY